A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine

Antiviral Chemistry and Chemotherapy

Volumn 18, Issue 5, 2007, Pages 297-300

  Borroto Esoda, Katyna ^a   Parkin, Neil ^b   Miller, Michael D ^a  

^a GILEAD SCIENCES   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

Author keywords

3TC; Antiviral drug resistance; FTC; HIV reverse transcriptase; NRTI

Indexed keywords

EMTRICITABINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; ASSAY; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION; PHENOTYPE; PRIORITY JOURNAL; VIROLOGY; VIRUS; VIRUS ISOLATION;

EID: 36849075696     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020701800505     Document Type: Article

References (13)

1. Benson CA, van der Horst C, Lamarca A, Haas DW, McDonald CK, Steinhart CR, Rublein J, Quinn JB, Mondou E, Rousseau F & FTC-303/350 Writing Group (2004) A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. AIDS 18:2269-2276.
2. Department of Health and Human Services (DHHS) (2006) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 10 October 2006. Retrieved October 10, 2006, from http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf
3. Feng JY, Myrick FT, Margot NA, Mulamba GB, Rimsky L, Borroto-Esoda K, Selmi B & Canard B (2006) Virologic and enzymatic studies revealing the mechanism of K65R- and Q151m-associated HIV-1 drug resistance towards emtricitabine and lamivudine. Nucleosides Nucleotides Nucleic Acids 25:89-107.
4. Feng JY, Shi J, Schinazi RF & Anderson KS (1999) Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. FASEB Journal 13:1511-1517.
5. Moore KH, Barrett JE, Shaw S, Pakes GE, Churchus R, Kapoor A, Lloyd J, Barry MG & Back D (1999) The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS 13:2239-2250.
6. Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C & Petropoulos CJ (2004) Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 48:437-443.
7. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ & Whitcomb JM. (2000) A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 44:920-928.
8. Richman DD (1997) Drug resistance and its implications in the management of HIV infection. Antiviral Therapy 2:41-58.
9. Ross LL, Parkin N, Gerondelis P, Chappey C, Underwood MR, St Clair MH & Lanier ER (2006) Differential impact of thymidine analogue mutations on emtricitabine and lamivudine susceptibility. Journal of Acquired Immune Deficiency Syndromes 43:567-570.
10. Rousseau FS, Wakeford C, Mommeja-Marin H, Sanne I, Moxham C, Harris J, Hulett L, Wang LH, Quinn JB, Barry DW & FTC-102 Clinical Trial Group (2003) Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. Journal of Infectious Diseases 188:1652-1658.
11. Schinazi RF (2003) Assessment of the relative potency of emtricitabine and lamivudine. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 34:243-245.
12. Skowron G, Whitcomb J, Wesley M, Petropoulos C, Hellman N, Holodniy M, Kolberg J, Detmer J, Wrin MT, Frost K for the American Foundation for AIDS Research Community Based Clinical Trials Network (1999) Viral load response to the addition of lamivudine correlates with phenotypic susceptibility to lamivudine and the presence of T215Y/F in the absence of M184V [abstract]. Antiviral Therapy 4 Suppl 1:55.
13. Wang LH, Begley J, St Claire RL 3rd, Harris J, Wakeford C & Rousseau FS (2004) Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Research and Human Retroviruses 20:1173-1182.